Shuh Narumiya Selected Research

asapiprant

1/2022	Eicosanoid signalling blockade protects middle-aged mice from severe COVID-19.
4/2021	Eicosanoid signaling as a therapeutic target in middle-aged mice with severe COVID-19.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shuh Narumiya Research Topics

Disease

58	Inflammation (Inflammations) 01/2022 - 04/2002
24	Neoplasms (Cancer) 12/2022 - 01/2002
10	Pain (Aches) 05/2011 - 07/2003
9	Contact Dermatitis (Eczema, Contact) 10/2019 - 06/2003
8	Fever (Fevers) 01/2017 - 09/2003
8	Asthma (Bronchial Asthma) 11/2016 - 04/2002
8	Stroke (Strokes) 10/2012 - 03/2007
7	Intracranial Aneurysm (Cerebral Aneurysm) 01/2019 - 01/2014
7	Carcinogenesis 07/2015 - 01/2002
6	Wounds and Injuries (Trauma) 04/2022 - 10/2006
6	Ischemia 01/2020 - 11/2003
6	Infarction (Infarctions) 10/2012 - 03/2007
6	Brain Ischemia (Cerebral Ischemia) 10/2012 - 03/2007
5	Alzheimer Disease (Alzheimer's Disease) 03/2015 - 11/2007
5	Fibrosis (Cirrhosis) 07/2012 - 09/2003
5	Hypersensitivity (Allergy) 07/2011 - 08/2003
5	Hyperalgesia 05/2011 - 07/2003
4	Infections 01/2022 - 08/2008
4	Rheumatoid Arthritis 09/2020 - 02/2006
4	Atopic Dermatitis (Atopic Eczema) 11/2019 - 08/2003
4	Autoimmune Diseases (Autoimmune Disease) 10/2019 - 03/2016
4	Hypertension (High Blood Pressure) 08/2019 - 01/2005
4	Neoplasm Metastasis (Metastasis) 12/2015 - 10/2006
4	Ischemic Stroke 01/2014 - 03/2009
4	Brain Injuries (Brain Injury) 01/2014 - 01/2009
4	Colonic Neoplasms (Colon Cancer) 10/2006 - 01/2002
4	Hypertrophy 07/2005 - 06/2002
3	Colitis 08/2020 - 04/2002
3	Immune System Diseases (Immune Disorders) 10/2019 - 01/2010
3	Necrosis 10/2019 - 11/2009
3	Dermatitis 01/2018 - 10/2013
3	Reperfusion Injury 01/2018 - 05/2004
3	Colorectal Neoplasms (Colorectal Cancer) 01/2017 - 01/2003
3	Pathologic Processes 03/2016 - 08/2008
3	Melanoma (Melanoma, Malignant) 12/2015 - 01/2008
3	Edema (Dropsy) 02/2014 - 03/2013
3	Gliosis 01/2014 - 04/2006
3	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2014 - 12/2009
3	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 10/2012 - 03/2007
3	Vascular Remodeling 10/2011 - 03/2010
3	Tachycardia (Tachyarrhythmias) 02/2011 - 11/2003
3	Cardiomegaly (Heart Hypertrophy) 02/2011 - 11/2003
3	Atherosclerosis 02/2011 - 09/2004
3	Disease Progression 07/2010 - 12/2009
2	COVID-19 01/2022 - 04/2021
2	Demyelinating Diseases (Demyelinating Disease) 11/2020 - 04/2006

Drug/Important Bio-Agent (IBA)

78	ProstaglandinsIBA 01/2022 - 01/2002
29	Dinoprostone (PGE2)FDA Link 01/2022 - 11/2003
19	Prostaglandins EIBA 07/2012 - 01/2002
17	Prostaglandin E Receptors (Prostaglandin E Receptor)IBA 08/2020 - 01/2002
13	Prostaglandin D2IBA 01/2022 - 04/2002
11	Epoprostenol (Prostacyclin)FDA LinkGeneric 01/2018 - 10/2002
11	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 07/2012 - 01/2002
10	Proteins (Proteins, Gene)FDA Link 01/2014 - 01/2002
9	Messenger RNA (mRNA)IBA 01/2022 - 01/2002
9	CytokinesIBA 01/2019 - 09/2003
8	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 01/2002
8	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2017 - 07/2002
8	Prostaglandin Receptors (Prostaglandin Receptor)IBA 05/2011 - 04/2002
7	ThromboxanesIBA 01/2022 - 01/2004
7	Prostaglandins DIBA 04/2021 - 06/2002
7	AntigensIBA 10/2019 - 06/2003
7	ChemokinesIBA 01/2019 - 03/2010
7	Epoprostenol ReceptorsIBA 01/2018 - 09/2004
7	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2017 - 01/2002
7	EnzymesIBA 07/2015 - 09/2004
6	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2014 - 01/2004
4	LipidsIBA 12/2022 - 02/2003
4	LigandsIBA 12/2022 - 02/2007
4	Transforming Growth Factor beta (TGF-beta)IBA 01/2022 - 07/2002
4	Dextrans (Dextran)FDA Link 08/2020 - 04/2002
4	Indomethacin (Indometacin)FDA LinkGeneric 11/2019 - 07/2003
4	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 01/2017 - 09/2005
4	Thromboxane Receptors (Thromboxane Receptor)IBA 07/2015 - 09/2004
4	salicylhydroxamic acid (SHAM)IBA 01/2014 - 04/2007
4	prostaglandin F2alpha receptorIBA 10/2013 - 01/2009
3	RNA (Ribonucleic Acid)IBA 04/2022 - 01/2019
3	prostaglandin D2 receptorIBA 01/2022 - 08/2014
3	EicosanoidsIBA 01/2022 - 01/2008
3	Pharmaceutical PreparationsIBA 04/2021 - 07/2003
3	Arachidonic Acid (Vitamin F)IBA 08/2019 - 08/2003
3	Interleukin-23 (Interleukin 23)IBA 01/2019 - 08/2010
3	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 01/2018 - 06/2014
3	HaptensIBA 01/2018 - 10/2009
3	Prostaglandin-E SynthasesIBA 01/2017 - 12/2015
3	AzoxymethaneIBA 01/2017 - 01/2002
3	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2017 - 04/2013
3	sodium sulfate (sodium bisulfate)FDA LinkGeneric 01/2017 - 04/2002
3	Interleukin-6 (Interleukin 6)IBA 07/2015 - 02/2006
3	SaltsIBA 01/2014 - 01/2005
3	Prostaglandins FIBA 10/2012 - 05/2005
3	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 03/2012 - 11/2007
3	4- (4- cyano- 2- (2- (4- fluoronaphthalen- 1- yl)propionylamino)phenyl)butyric acidIBA 02/2010 - 04/2002
2	lysophosphatidic acidIBA 12/2022 - 10/2005
2	asapiprantIBA 01/2022 - 04/2021
2	Phospholipases (Phospholipase)IBA 01/2022 - 12/2009
2	Immunoglobulin E (IgE)IBA 11/2019 - 09/2003

Therapy/Procedure

7	Therapeutics 01/2022 - 12/2009
4	Chemoprevention 01/2017 - 02/2005
3	Ligation 08/2019 - 01/2014